Suppr超能文献

对中枢神经系统阳性的幼儿急性淋巴细胞白血病不进行颅脑放疗的治疗。

Treatment of young children with CNS-positive acute lymphoblastic leukemia without cranial radiotherapy.

作者信息

Wilejto Marta, Di Giuseppe Giancarlo, Hitzler Johann, Gupta Sumit, Abla Oussama

机构信息

Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada.

出版信息

Pediatr Blood Cancer. 2015 Nov;62(11):1881-5. doi: 10.1002/pbc.25620. Epub 2015 Jul 7.

Abstract

BACKGROUND

Due to the long-term sequelae of cranial radiotherapy (CRT), contemporary treatment protocols for children with acute lymphoblastic leukemia (ALL) aim to limit the use of prophylactic CRT. For patients with central nervous system (CNS) involvement with ALL at diagnosis, the use of CRT remains common. Children <5 years of age are a particularly challenging subgroup in whom the consequences of CRT can be devastating.

PROCEDURE

This study retrospectively describes the overall (OS) and event-free survival (EFS) of young children (1-5 years) who were treated for CNS-positive ALL at the Hospital for Sick Children between 2000 and 2013.

RESULTS

Of a total of 19 patients, two were treated with upfront CRT, both as part of the conditioning regimen prior to HSCT. All patients received intensification of CNS-directed chemotherapy by triple intra-thecal chemotherapy (84.2%), use of dexamethasone in induction (57.9%) and maintenance (66.7%), and high-dose methotrexate (77.8%). The OS was 84.2 ± 8.4% and EFS was 79.0 ± 9.4% with a median follow-up time of 4.3 years (range, 2.6-8.2). The cumulative incidence of CNS relapse was 5.2 ± 5.1%.

CONCLUSIONS

We conclude that omission of CRT from the treatment of young children with ALL involving the CNS is associated with acceptable survival and avoids potentially devastating late effects in this group.

摘要

背景

由于颅脑放射治疗(CRT)的长期后遗症,当代急性淋巴细胞白血病(ALL)儿童治疗方案旨在限制预防性CRT的使用。对于诊断时伴有中枢神经系统(CNS)受累的ALL患者,CRT的使用仍然很常见。5岁以下儿童是一个特别具有挑战性的亚组,CRT的后果可能是毁灭性的。

程序

本研究回顾性描述了2000年至2013年间在病童医院接受CNS阳性ALL治疗的幼儿(1 - 5岁)的总生存期(OS)和无事件生存期(EFS)。

结果

在总共19例患者中,2例接受了 upfront CRT治疗,均作为HSCT前预处理方案的一部分。所有患者均通过三联鞘内化疗(84.2%)、诱导期(57.9%)和维持期(66.7%)使用地塞米松以及高剂量甲氨蝶呤(77.8%)强化中枢神经系统导向化疗。中位随访时间为4.3年(范围2.6 - 8.2年),OS为84.2 ± 8.4%,EFS为79.0 ± 9.4%。CNS复发的累积发生率为5.2 ± 5.1%。

结论

我们得出结论,在治疗伴有CNS受累的ALL幼儿时省略CRT与可接受的生存率相关,并避免了该组潜在的毁灭性晚期效应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验